2.2.2. Participants
endometrial cancer, infections, cancer of the digestive, hematuria, dysuria, cystitis, tenderness/pain
RECURRENT URINARY TRACT INFECTION, ENDOMETRIAL CANCER, RECURRENT URINARY TRACT INFECTION, CNS INFECTIONS, INFECTIONS, HEMATURIA, CYSTITIS
Participants were recruited through advertisements (posters, social media, and personal electronic mail from the public sector) from the community in Northern Denmark, at the North Denmark Regional Hospital, and Aalborg University Hospital. The first woman was enrolled in September 2019, and the last was enrolled in October 2021. Eligible participants were postmenopausal women with OAB with a minimum of five years since their last menstruation. Exclusion criteria were the use of systemic or local hormonal replacement therapy; intake of RCE or other isoflavone-rich supplements; use of prebiotic and/or probiotic supplements or receiving any antibiotics within three months prior to inclusion; recurrent urinary tract infections (defined as ≥2 infections in the last six months or ≥3 infections during the last year); current urinary tract infection (defined as a positive urine culture together with symptoms of cystitis, including dysuria, suprapubic tenderness/pain, hematuria, frequent urination, and urgency); and current or prior history of breast-, ovary-, or endometrial cancer and/or cancer of the digestive and/or urinary tract. Moreover, women who had used a levonorgestrel-releasing intrauterine device within the last five years and/or had a hysterectomy before the cessation of menstrual periods and were younger than 60 years were also excluded. 